Impact of primary prophylaxis on febrile neutropenia within community practices in the US

Journal of Medical Economics

Volumn 12, Issue 3, 2009, Pages 203-210

  Hershman, Dawn ^a   Hurley, Dana ^b   Wong, Mitchell ^c   Morrison, Vicki A ^d   Malin, Jennifer L ^e  

^a Howard Hughes Medical Institute   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Febrile neutropenia; Filgrastim; G CSF; Growth factors; Pegfilgrastim

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIMARY PREVENTION; PROPHYLAXIS; SOLID TUMOR; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FILGRASTIM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 75149155846     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903238603     Document Type: Article

References (29)

1. Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2003;23:15-19S.
2. Crawford J, Dale D, Lyman G. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
3. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557-571.
4. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
5. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-1211.
6. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
7. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993;4:651-656.
8. Crawford J. The importance of chemotherapy dose intensity in lung cancer. Semin Oncol 2004;31:25-31.
9. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
10. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-324.
11. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184.
12. Glaspy J, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993;29A:S23-30.
13. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
14. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-909.
15. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-519.
16. Kuderer NM, Dale DC, Crawford J. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-3167.
17. Patton J, Fridman M, Perry T, Masaquel A. Trends in chemotherapy and growth factor administration for early stage breast cancer and intermediate grade non-Hodgkin's lymphoma patients. Abstract presented at Multinational Association of Supportive Care in Cancer (MASCC) in Toronto, Canada, 2006.
18. Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manage Care Pharm 2007;13:337-348.
19. Fortner B, Stolshek B, Mao Q, Schwartzberg L. Association of IV antibiotic use and hospitalisation with filgrastim (F) and pegfilgrastim (PegF) utilization in a community oncology clinic sample. In: 40th ASHP Midyear Clinical Meeting and Exhibition, 2003, December 7-11, 2003; New Orleans, LA, 2003.
20. Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manage Care Pharm 2003;9:15-21.
21. Swanson G, Bergstrom K, Stump E, et al. Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol 2000;18:1764-1770.
22. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
24. United States Department of Health and Human Services. Health Insurance Portability and Accountability Act (HIPAA)
25. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
26. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564-1571.
27. Smith TC, Khatcheressian J, Lyman G, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:1-19.
28. National Comprehensive Cancer Network clinical practice guidelines in oncology. Myeloid Growth Factors, version 1.2009 [online].
29. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-2453.